E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients suffering from keratoconjunctivitis sicca (dry eye) and break-up-time (BUT) values < 10 sec |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of the study is to investigate the tolerability of Vitagel in comparison to Liposic after repeated ocular applications over 12 months in patients with keratoconjunctivitis sicca as requested by the competent authority (BfArM)
Primary objective Subjective assessment of tolerability (sum score of itching, burning and discomfort) at the 6 ± 1 week assessment time point, comparison between treatment groups (non-inferiority) |
|
E.2.2 | Secondary objectives of the trial |
Secondary objectives Subjective assessment of tolerability (sum score of itching, burning and discomfort) 14 ± 2 days, 16 ± 2 weeks, 32 ± 2 weeks and 12 months ± 2 weeks after start of treatment, comparison between treatment groups (non-inferiority) Signs for irritation (corneal stipples, chemosis and injection) at all assessment time points, comparison between treatment groups (non-inferiority) Subjective assessment of keratoconjunctivitis sicca by patients (dryness, sand grain feeling, burning, itching and pain) at all assessment time points, comparison between treatment groups (non-inferiority) Break-up-time (BUT) at all assessment time points, comparison between treatment groups (non-inferiority) Assessment of blurred vision at each assessment time point· Safety parameters |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
Male and female patients with keratoconjunctivitis sicca and BUT < 10 sec. Age 18 to 70 willingness to actively participate in the study and to come to the scheduled visits willingness to adhere to the study procedures signed written informed consent to participate in the study negative urine pregnancy test (in female patients of child bearing potential) for female patients of childbearing potential: signed written confirmation to use safe contraception (hormonal contraceptive method, condom with spermicidal agent, IUD, diaphragm combined with spermicidal creams, sterilized partner, sexual abstinence)
|
|
E.4 | Principal exclusion criteria |
any active ophthalmologic disease other than keratoconjunctivitis sicca patients using currently (at screening) ophthalmic medications artificial tear products 7 days prior to the start of the study and 7 days prior to the screening known allergy against peanuts or soy beans acute ocular infection and/or inflammation within one month prior to the start of the study patients who had ocular surgery within the last 6 months prior to the start of the study patients with a history of recurrent inflammatory diseases of the eyes patients wearing contact lenses pregnancy or lactation severe illness on account of which the patient should not participate in the study in the opinion of the investigator known incompatibility or allergy against the test or reference product psychiatric conditions that might limit the participation in the trial and/or that lead to the assumption that the ability to completely understand the consequences of consent is missing any history of drug addiction or alcoholism in the past 3 years infectious diseases (e.g. hepatitis or AIDS) patients with poor compliance participation in a clinical trial within the last 30 days prior to the start of this study patients underlying any other restrictions due to the participation in other tests / test institutes employees of the study sites or of the Sponsor company if in the opinion of the investigator the patient should not participate in the study for any reason
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoint: Tolerability Sum Score (itching, burning, discomfort) after six weeks of product application: Analysis of non-inferiority of Vitagel® with respect to Liposic® |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Information not present in EudraCT |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Information not present in EudraCT |
E.6.6 | Pharmacokinetic | Information not present in EudraCT |
E.6.7 | Pharmacodynamic | Information not present in EudraCT |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Information not present in EudraCT |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Post treatment details are described in the study protocol. Follow-up visits beyond the 12-month investigational period are not planned but the patients will be instructed that they may return to the study site after the end of the trial for further medical examinations in case they have medical problems that might be related to the study. All AEs will e followed by the investigator until they are either solved or until a stabel status is reached. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |